Sonodynamic therapy with photofrin II on AH130 solid tumor. Pharmacokinetics, tissue distribution and sonodynamic antitumoral efficacy of photofrin II.
BACKGROUND
The pharmacokinetics and tissue distribution of photofrin II (PF) and its efficacy in sonodynamic therapy were studied in rats bearing AH130 solid tumors.


METHODS
In order to find the optimum timing of the ultrasound exposure after administration of PF, the PF concentrations in plasma, skin, muscle and tumor were measured and pharmacokinetically analyzed. Antitumor effects were estimated by measuring tumor size.


RESULTS
Since the highest concentration of PF in tumors occurred 24 h after administration, ultrasound administration 24 h after the intravenous administration of PF was chosen. Ultrasound alone showed a slight antitumor effect, which became increasingly significant as the dose of PF was increased, while PF alone showed no significant effect.


CONCLUSIONS
PF significantly sensitized solid tumors to the antitumor effect of ultrasound in a synergistic manner.
Yumita
N
N
School of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan.
Umemura
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D017323:Dihematoporphyrin Ether / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D009368:Neoplasm Transplantation; D051381:Rats; D013997:Time Factors; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D014464:Ultrasonic Therapy
D000970:Antineoplastic Agents; D017323:Dihematoporphyrin Ether